Comparing the current results to its competitors, Lipocine Inc reported Revenue decrease in the 2 quarter 2026 year on year by -69.48 %, despite the revenue increase by the most of its competitors of 21.53 %, recorded in the same quarter.
Lipocine Inc 's Comment on Competition and Industry Peers
Orphan drug exclusivity provides a seven-year period during which approval of the same drug for the same indication or disease can be blocked if a competitor obtains approval for that drug or if the drug candidate is included in the competitor's product. The FDA's Priority Review designation expedites the review process for New Drug Applications (NDAs) compared to the Standard review. Additionally, government programs negotiate drug prices for certain single-source brand drugs or biologics under Medicare Part D and Part B, which include excise taxes and rebates related to price increases exceeding inflation.
Amarin Corp Plcuk's business model revolves around the development, commercialization, and marketing of innovative pharmaceutical products, particularly focused on cardiovascular health.
Ac Immune Sa is a biopharmaceutical company that focuses on developing precision medicine to target neurological and neurodegenerative diseases. Their business model revolves around leveraging their proprietary technology platforms and partnerships with pharmaceutical companies to advance their drug discovery and development programs. Through licensing agreements and collaborations, they aim to bring innovative therapeutics to the market that address the urgent unmet needs in the field of neurology.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Verve Therapeutics Inc is a biotechnology company specialized in developing transformative medicines that could permanently prevent cardiovascular diseases through gene editing technology. Their business model revolves around leveraging cutting-edge gene editing techniques to develop novel therapeutics targeting specific genes associated with heart diseases. By utilizing this approach, Verve aims to provide long-term solutions for individuals at risk of cardiovascular ailments, addressing a significant unmet need in the healthcare industry.
Sources:
Lipocine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lipocine Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
